Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting

ConferenceNext-gen IO pipelineADC pipelinePositive

AI Analysis

Summary

Innovent Biologics announced it will present new clinical data on its next-generation immuno-oncology and ADC pipeline candidates at the 2026 ESMO Annual Meeting.

Importance:4/10

Sentiment:

0.30

conference presentationimmuno-oncologyADCpipeline update

Related Companies

$DFPH $CHHE $WHEN

Read the original article

Published by PR Newswire Clinical Trials on September 23, 2026 8:48 AM

Read Original